Abstract:
Aim: To explore the goals and outcomes of public procurement of drug treatment services in OECD countries. The study explores how these complex services are procured and delivered. Methods and data: A systematic review of the literature (1990-2020) identified four partly overlapping models of drug treatment service procurement that are here labelled traditional, value-based, outcome-based, and innovative. Results: Even though different forms of drug treatment services procurement are common, only 12 empirical studies that focused on procurement were found. The four models differ in their approaches to design and performance specifications and the role of competition and collaboration in the co-creation of value. Conclusions: Competition and incentives improve neither the efficiency nor the quality or the outcomes of complex drug treatment services. Whereas many studies focus on payment mechanisms, there are important research gaps that relate to the co-creation of value with and for the service-users and other stakeholders.
摘要:
目的:探讨OECD国家公共采购药物治疗服务的目标和成果。该研究探讨了如何采购和交付这些复杂的服务。方法和数据:对文献(1990-2020)的系统回顾确定了四个部分重叠的药物治疗服务采购模型,这些模型在此标记为传统,基于价值,基于结果,和创新。结果:尽管不同形式的药物治疗服务采购很常见,只有12项侧重于采购的实证研究被发现。这四种模式在设计和性能规格的方法以及竞争和协作在共同创造价值中的作用方面有所不同。结论:竞争和激励既不能提高复杂药物治疗服务的效率,也不能提高其质量或结果。尽管许多研究集中在支付机制上,在与服务用户和其他利益相关者共同创造价值方面,存在重要的研究差距。